HumanNaturalKiller(NK)Cell

NaturalKiller(NK)cellsarelymphocytesoftheimmunesystemthatarecriticalinhostdefenseandimmuneregulationaspartofboththeinnateandadaptiveimmuneresponse.Theyareofparticularinteresttoimmunotherapyresearchersastheyholdthepromisetospecificallytargetanddestroycancercellsandtumorswhileleavinghealthycellsintact.

CellsYouCanCountontoPerform

NaturalKillercellsaretrADItionallycharacterizedbythepresenceoftheCD56cellsurfaceMarkerandabsenceofCD3.Inaddition,CD16isimportantforNKcellfunctionbecauseCD16inducescytokineexpressionandcytotoxiceffectoractivity.

LonzaNKcellsareisolatedusingpositive(2W-502)ornegative(2W-501)immunomagneticselectionfortheCD56marker.Purityis≥90%basedonthepresenceofCD56+cells.

BothpositivelyandnegativelyselectedNKcellsareguaranteedtoexpressCD56andCD16.However,negativeimmunomagneticseparationofNKcellsresultsinsignificantlygreaterenrichmentofCD16+cells(typically>80%oftotalcells),whereasexpressionofCD16isvariablewiththepositivelyselectedNKcells. 

LonzaNKcellsareguaranteedtoexpressCD56andCD16,andcontain≥5millionviablecellspervial.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.

ChoicesinCellTypeandTissueSource

ExpressionofCD56andCD16cangreatlyinfluencecellfunction.Inaddition,selectiontechniquescanalsoinfluencefunctionofyourtargetcells.That"swhyLonzaoffersbothpositivelyandnegativelyselectedNKcellsandcharacterizestheexpressionlevelsofbothCD56andCD16ineverylotofcells. 

Wealsoofferchoicesintissuesourceifperipheralbloodderivednaturalkillercellsaren"twhatyou"relookingfor.CordbloodMNCsorbonemarrowMNCscanbedepletedoflineagemarkerexpressingcellsinordertoisolateNKcells.Inaddition,cordbloodCD34+cellsorbonemarrowCD34+cellscanbedifferentiatedintonaturalkillercells.

SupportedbyLonzaMedium

LGM-3™LymphocyteGrowthMediumisrecommendedforoptimalperformanceofNKcells.Additionalcytokinesmaybenecessarydependingonapplication.

LonzaguaranteestheperformanceofClonetics™/Poietics™cellsonlyifappropriateClonetics™/Poietics™mediaandreagentsareusedexclusivelyandtherecommendedstorageanduseprotocolsarefollowed.Anymodificationsmadetotherecommendedcellsystemsincludingtheuseofalternativemedia,reagentsorprotocols,willvoidcellandmediaperformanceguarantees.Ifyouneedassistanceinselectingtheappropriatemedia,reagents,orprotocol,pleasecontactLonzaScientificSupport.

龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。